(Q44403615)

https://api.crossref.org/works/10.1124/DMD.31.5.565

2 December 2017

title

Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19 (English)

1 reference

24 December 2023

1 reference

pharmaceutical science

1 reference

https://api.crossref.org/works/10.1124/DMD.31.5.565

24 December 2023

1 reference

https://api.crossref.org/works/10.1124/DMD.31.5.565

24 December 2023

4

Evan D Kharasch

1 reference

2 December 2017

Caiping Yao

1

1 reference

2 December 2017

Kent L. Kunze

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12695344

24 December 2023

William F. Trager

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12695344

24 December 2023

René H. Levy

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12695344

24 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12695344

24 December 2023

publication date

1 May 2003

1 reference

full work available at URL

2 December 2017

https://syndication.highwire.org/content/doi/10.1124/dmd.31.5.565

1 reference

https://api.crossref.org/works/10.1124/DMD.31.5.565

Drug Metabolism and Disposition

24 December 2023

published in

1 reference

2 December 2017

volume

31

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

565-571

1 reference

High performance liquid chromatography with ultraviolet detection used for laboratory routine determination of fluvoxamine in human plasma.

2 December 2017

cites work

https://api.crossref.org/works/10.1124/DMD.31.5.565

2

1 reference

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

4

1 reference

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

5

1 reference

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

8

1 reference

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

9

1 reference

Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

10

1 reference

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

14

1 reference

Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

15

1 reference

Fluvoxamine-Clozapine Drug Interaction: Inhibition In Vitro of Five Cytochrome P450 Isoforms Involved in Clozapine Metabolism

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

17

1 reference

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

18

1 reference

Clinical pharmacokinetics of fluvoxamine

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

19

1 reference

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

20

1 reference

Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

21

1 reference

Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

23

1 reference

Kinetics of drug metabolism inhibition: Use of metabolite concentration-time profiles

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

24

1 reference

Inhibitors of imipramine metabolism by human liver microsomes

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

25

1 reference

The major fluvoxamine metabolite in urine is formed by CYP2D6.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

26

1 reference

Non-linear fluvoxamine disposition

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

27

1 reference

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

28

1 reference

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

29

1 reference

In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

30

1 reference

Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

31

1 reference

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

32

1 reference

Inhibition-based metabolic drug-drug interactions: predictions from in vitro data

24 December 2023

https://api.crossref.org/works/10.1124/DMD.31.5.565

33

1 reference

24 December 2023

Identifiers

DOI

10.1124/DMD.31.5.565

1 reference

release_hsljsdm7mbdzlo3wpuyojvxfvm

2 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hsljsdm7mbdzlo3wpuyojvxfvm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference